KYMERA THERAPEUTICS, INC. Finance Lease, Weighted Average Discount Rate, Percent
KYMERA THERAPEUTICS, INC. (KYMR) had Finance Lease, Weighted Average Discount Rate, Percent of 8.86% as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-05
- 2026-06-30: Finance Lease, Weighted Average Discount Rate, Percent 8.86%.
- 2026-03-31: Finance Lease, Weighted Average Discount Rate, Percent 8.82%.
- 2025-12-31: Finance Lease, Weighted Average Discount Rate, Percent 8.80%.
- 2025-09-30: Finance Lease, Weighted Average Discount Rate, Percent 8.78%.
| Period end | Finance Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 8.86% 10-Q · filed 2026-08-05 |
| 2026-03-31 | 8.82% 10-Q · filed 2026-04-30 |
| 2025-12-31 | 8.80% 10-K · filed 2026-02-26 |
| 2025-09-30 | 8.78% 10-Q · filed 2025-11-04 |
| 2025-06-30 | 8.75% 10-Q · filed 2026-08-05 |
| 2025-03-31 | 8.68% 10-Q · filed 2026-04-30 |
| 2024-12-31 | 8.70% 10-K · filed 2026-02-26 |
| 2024-09-30 | 8.58% 10-Q · filed 2025-11-04 |
| 2024-06-30 | 8.14% 10-Q · filed 2025-08-11 |
| 2024-03-31 | 8.17% 10-Q · filed 2025-05-09 |
| 2023-12-31 | 8.20% 10-K · filed 2025-02-27 |
| 2023-09-30 | 8.48% 10-Q · filed 2024-10-31 |
| 2023-06-30 | 8.50% 10-Q · filed 2024-08-07 |
| 2023-03-31 | 8.52% 10-Q · filed 2024-05-02 |
| 2022-12-31 | 8.50% 10-K · filed 2024-02-22 |
| 2022-09-30 | 8.73% 10-Q · filed 2023-11-02 |
| 2022-06-30 | 8.74% 10-Q · filed 2023-08-03 |
| 2022-03-31 | 8.75% 10-Q · filed 2023-05-04 |
| 2021-12-31 | 8.80% 10-K · filed 2023-02-23 |
| 2021-09-30 | 8.75% 10-Q · filed 2022-11-03 |
| 2021-06-30 | 8.51% 10-Q · filed 2022-08-09 |
| 2021-03-31 | 8.12% 10-Q · filed 2022-05-03 |
| 2020-12-31 | 8.00% 10-K · filed 2022-02-24 |
| 2020-09-30 | 8.10% 10-Q · filed 2021-11-10 |
| 2020-06-30 | 7.90% 10-Q · filed 2021-08-06 |
| 2020-03-31 | 7.71% 10-Q · filed 2021-05-06 |
| 2019-12-31 | 7.80% 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |